Back

Monetary costs and LDL-C reduction from upfront combination lipid-lowering therapy with ezetimibe in an irish ACS cohort

4 April 2025 (11:00 - 11:45)
Organised by: Logo
Congress Presentation Part of: Dyslipidaemia management in 2025: status quo and best practice (2) Secondary Prevention EAPC Premium Access ESC Preventive Cardiology 2025 European Association of Preventive Cardiology (EAPC)

About the speaker

Photo
Doctor Dominic Butler

Galway University Hospital, Galway (Ireland)

5 More presentations in this session

Presentation thumbnail
Gender differences in the management of dyslipidemia in Switzerland
Doctor R. de La Harpe (Lausanne, CH)
Abstract Slides
Presentation thumbnail
Prevalence and clinical relevance of familial hypercholesterolemia-causing mutations in Germany
Doctor N. Arnold (Hamburg, DE)
Abstract Slides
Presentation thumbnail
More musculoskeletal disorders and poor pain management in patients with familial hypercholesterolemia and self-perceived side effects to cholesterol-lowering treatment
Ms A. Uduma (Oslo, NO)
Abstract Slides
Presentation thumbnail
Evaluation of LDL levels and lipid optimisation in high cardiovascular risk patients in nurse-led clinics in Ireland: a cross-sectional study
Mrs M. Brennan (Waterford, IE)
Abstract Slides
Presentation thumbnail
Comparative effectiveness of novel anti-hyperlipidemic drugs in adults with hyperlipidemia: a systematic review and bayesian network meta-analysis
Doctor V. Lanari (Milan, IT)
Abstract Slides

Access the full session

Session thumbnail
Dyslipidaemia management in 2025: status quo and best practice (2)

The Event

Event poster

ESC Preventive Cardiology 2025

4 April 2025 11:00 CET
You may be interested in
thumbnail
Congress Presentation
Real-world use of rosuvastatin 40 mg and ezetimibe 10 mg after ACS: is this combination effective in achieving guideline-recommended LDL-C goals after discharge?
thumbnail
Congress Presentation
Does early initiation of non-statin therapy, evolocumab with LDL-C <50mg/dL contribute to the reduction of hospital readmissions in patients with ACS?: a single center real world evidence from ELAINE
thumbnail
Congress Presentation
Impact of bempedoic acid alone and combined with ezetimibe on ldl-cholesterol reduction: graphical evidence and retrospective analysis of a real-world clinical cohort

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources